Loading stock data…
United Therapeutics Corporation (UTHR)
$544.92+2.26 (+0.42%)
Market ClosedLast close Jun 29
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
United Therapeutics Corporation in the Healthcare sector is trading at $544.92 with a market capitalization of $23.3B. Wall Street consensus targets $665.23 (13 analysts), implying a +22.1% move over the next 12 months. The stock is currently near its 52-week high of $609.35, remaining 8.6% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +22.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $781.50M↓ | $790.20M↓ | $799.50M↑ | $798.60M↑ | $794.40M |
| Gross Profit | $648.10M↓ | $686.80M↓ | $698.60M↓ | $711.00M↑ | $701.90M |
| Operating Income | $325.80M↓ | $357.50M↓ | $389.30M↑ | $386.20M↑ | $382.80M |
| Net Income | $274.90M↓ | $364.30M↑ | $338.70M↑ | $309.50M↓ | $322.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$23.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.31
Beta
Defensive asset. Lower volatility than the S&P 500.
0.59
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
21.82%
Volume
Today's trading volume
412,281
Recent News
Is MannKind Corporation (MNKD) A Good Stock To Buy Now?
Is MNKD a good stock to buy? We came across a bullish thesis on MannKind Corporation on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on MNKD. MannKind Corporation’s share was trading at $3.8400 as of June 24th. MNKD’s trailing and forward P/E were 178.00 and 40.49 respectively according to Yahoo Finance. MannKind […]
Bull of the Day: Neurocrine Biosciences (NBIX)
Neurocrine Biosciences (NBIX) has quietly become one of biotech's strongest earnings stories.
Q1 Earnings Outperformers: United Therapeutics (NASDAQ:UTHR) And The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR).
These 3 Stocks Lowered Their Share Counts Drastically in Q1
Pinterest, Southwest Airlines, and United Therapeutics each executed significant share repurchases in Q1 2026, reducing their outstanding share counts by 16%, 5%, and 3.2%, respectively.
A Look At United Therapeutics (UTHR) Valuation After Strong Long Term Shareholder Returns
United Therapeutics overview United Therapeutics (UTHR) has drawn investor attention after recent share price moves, with the stock last closing at US$549.87. The company focuses on therapies for chronic and life-threatening diseases, primarily serving patients in the United States. See our latest analysis for United Therapeutics. Recent trading has been choppy, with a 1-day share price return of 0.40% and a 30-day share price return down 7.86%. However, the 1-year total shareholder return of...